Diltiazem Dosing for Supraventricular Tachycardia (SVT)

Acute Management of SVT

• The American Heart Association recommends intravenous diltiazem administration at 0.25 mg/kg IV bolus over 2 minutes, with the option to increase to a maintenance infusion at 5-10 mg/h, up to 15 mg/h if needed, for acute treatment of SVT 1
• Vagal maneuvers should be attempted first for acute treatment of regular SVT, according to the American College of Cardiology 2
• Intravenous diltiazem is highly effective as second-line therapy for acute termination of SVT in hemodynamically stable patients, with a recommended initial dose of 0.25 mg/kg IV bolus administered over 2 minutes, as suggested by the American Heart Association 1, 2

Alternative Agents

• Synchronized cardioversion is recommended for hemodynamically stable patients when pharmacological therapy is ineffective, as stated by the American College of Cardiology and the American Heart Association 2, 3
• Verapamil (5-10 mg IV bolus over 2 minutes) can be used as an alternative calcium channel blocker, according to the American Heart Association 1

Important Precautions and Contraindications

• The American Heart Association advises against using diltiazem in patients with AV block greater than first degree or SA node dysfunction (in absence of pacemaker), as well as in patients with Wolff-Parkinson-White syndrome with atrial fibrillation/flutter, hypotension or decompensated systolic heart failure, and cardiogenic shock 1
• The American College of Cardiology recommends avoiding diltiazem in patients with certain conditions due to potential adverse effects, including worsening heart failure in patients with pre-existing ventricular dysfunction, bradycardia, and abnormal liver function (rare) 1

Drug Interactions

• The American Heart Association suggests using diltiazem with caution when combined with other drugs that have SA and/or AV nodal-blocking properties, as it is a substrate of CYP3A4 and a moderate CYP3A4 inhibitor 1

Acute and Ongoing Management of Supraventricular Tachycardia (SVT)

Acute Management

• The American Heart Association recommends adenosine as the first-line medication for acute treatment of SVT, with success rates of approximately 95% for terminating AVNRT and 90-95% for orthodromic AVRT 4, 5
• Vagal maneuvers should be attempted first for acute treatment of regular SVT, with Valsalva maneuver being more successful than carotid sinus massage (overall success rate of 27.7% when both techniques are used) 6, 7
• Synchronized cardioversion should be performed immediately for hemodynamically unstable patients when vagal maneuvers and adenosine fail or are not feasible 8, 9
• Intravenous calcium channel blockers (diltiazem or verapamil) are particularly effective for acute termination of SVT with success rates of 64-98% 10, 9
• Intravenous beta blockers can be used, though they have limited evidence for effectiveness compared to calcium channel blockers 6, 9

Ongoing Management

• The American College of Cardiology recommends oral verapamil or diltiazem for long-term management in patients who are not candidates for, or prefer not to undergo, catheter ablation 4, 11
• Oral beta blockers are useful for ongoing management in patients with symptomatic SVT who do not have ventricular pre-excitation during sinus rhythm 6, 10
• Flecainide is reasonable for ongoing management in patients without structural heart disease who have symptomatic SVT and are not candidates for catheter ablation 6

Important Considerations and Precautions

• Calcium channel blockers (diltiazem, verapamil) should be avoided in patients with ventricular tachycardia or pre-excited AF (can cause hemodynamic instability and ventricular fibrillation) 4, 9
• Calcium channel blockers (diltiazem, verapamil) should be avoided in patients with systolic heart failure 4, 11

Intravenous Diltiazem for Supraventricular Tachycardia

Critical Decision Point: Hemodynamic Stability

• The American Heart Association recommends proceeding directly to synchronized cardioversion in hemodynamically unstable patients with supraventricular tachycardia, as pharmacological rate control can delay definitive treatment and worsen outcomes 12, 13, 14
• In hemodynamically stable patients, intravenous diltiazem is highly effective for acute rate control in atrial fibrillation, atrial flutter, or other supraventricular tachycardias 12, 13, 14

Alternative Agents When Diltiazem Contraindicated

• The American College of Cardiology recommends esmolol as a preferred IV beta-blocker for patients without severe heart failure or reactive airway disease when diltiazem is contraindicated 13, 14
• IV amiodarone is recommended for patients with systolic heart failure when beta-blockers are contraindicated or ineffective 12, 15
• Immediate cardioversion remains the safest option for any patient with hemodynamic compromise 12, 13, 14

Diltiazem Use in Atrioventricular Nodal Re‑entrant Tachycardia (AVNRT)

Acute Intravenous Management

• The American College of Cardiology (ACC) and American Heart Association (AHA) recommend an initial IV bolus of diltiazem 0.25 mg/kg administered over 2 minutes for hemodynamically stable AVNRT; if additional rate control is needed, a continuous infusion of 5–15 mg/hour may be started. [16][17]
• After vagal maneuvers have failed, IV diltiazem is a highly effective first‑line pharmacologic option, achieving acute conversion in 64–98 % of patients with stable AVNRT. [16][17]
• In head‑to‑head trials, diltiazem was more successful than the β‑blocker esmolol for terminating supraventricular tachycardia, supporting its preferential use when a β‑blocker is considered. [16][17]

Oral Maintenance Therapy

• For patients who decline or are unsuitable for catheter ablation, the ACC/AHA guidelines assign a Class I recommendation (Level B‑R) to oral diltiazem as chronic therapy, emphasizing its role in symptom control and prevention of recurrence. [16][17]
• Initiate extended‑release diltiazem at 120 mg once daily; titrate gradually over several weeks to a target range of 120–360 mg daily based on symptom relief and tolerability. [16][17]

Role in the Treatment Algorithm

• Catheter ablation of the slow‑pathway remains the first‑line definitive treatment for symptomatic AVNRT, offering a potential cure; oral diltiazem is positioned as an alternative for patients who are not candidates for, or who refuse, ablation. [16][17]

Contraindications and Critical Precautions

• Absolute contraindications (Class III recommendation):
  
  • Second‑ or third‑degree AV block without a functioning pacemaker. [16][17]
  • Decompensated systolic heart failure or severe left‑ventricular dysfunction, owing to diltiazem’s negative inotropic effect. [16][17]
  • Wolff‑Parkinson‑White syndrome with atrial fibrillation or flutter, because diltiazem can accelerate ventricular response via the accessory pathway and precipitate ventricular fibrillation. [16][17]
• Critical safety pitfall: Diltiazem must never be administered for a wide‑complex tachycardia unless the rhythm is definitively identified as supraventricular; use in ventricular tachycardia can cause hemodynamic collapse. [16][17]
• High‑risk drug combination: Concomitant use of β‑blockers with diltiazem markedly increases the risk of severe bradyarrhythmias, profound AV block, and heart‑failure exacerbation; avoidance is advised, and if co‑administration is unavoidable, intensive monitoring of heart rate and PR interval is required. 17